pregabalin and Sexual-Dysfunction--Physiological

To investigate the role of pregabalin in relieving USRS in patients with an indwelling double-J (DJ) stents.. A total of 500 adult patients with a unilateral single ureteral stone who underwent ureteroscopic stone management and required DJ stent insertion were prospectively included in our study. Patients were blindly assigned into four groups A, B, C and D. Those in group A were managed with combination of solifenacin 5-mg tablets and pregabalin 75-mg capsules bid. Patients in group B were managed with solifenacin 5-mg tablets. Those in group C were managed with pregabalin 75-mg capsules bid. Those in group D were control group. All patients were evaluated on day 15 postoperatively for stent-related symptoms using the Arabic translated and validated ureteral stent symptom questionnaire (USSQ).. The total USSQ score as well as general health index was significantly lower in group A as compared to other groups. In addition, urinary symptom index was significantly improved in both groups A and B as compared to group C and group D. Pain symptom index was significantly improved in both groups A and C as compared to groups B and D. No statistically significant difference was reported regarding sexual index and work performance index among the whole study groups.. Pregabalin appears to be a well-tolerated, safe and effective drug in reducing most of USRS, especially relief of pain with subsequent improvement of patient's quality of life. Its combination with solifenacin should be considered to manage patients with USRS as it shows a significant improvement in total USSQ score and general health index when compared to each drug alone.

Topics: Adult; Analgesics; Drug Therapy, Combination; Female; Flank Pain; Hematuria; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Pregabalin; Prospective Studies; Quality of Life; Sexual Dysfunction, Physiological; Single-Blind Method; Solifenacin Succinate; Stents; Surveys and Questionnaires; Ureter; Ureteral Calculi; Urological Agents

Persistent genital arousal disorder (PGAD) is a rare condition in women that causes a lot of suffering. The pathophysiology is not well understood and an approach promising effective treatment has not been established so far.. This study aims to make colleagues aware of two treatment options, which proved to be successful in one case each and which might be worth further investigation.. Subjective distress from unwanted sexual arousal, unwanted orgasms, and pain in the genital area.. Treatment of two women--36 and 41 years old--suffering from PGAD with duloxetine and pregabalin, respectively.. In both women, the treatment proved to be very successful over a long period of time. One of them experienced full remission (duloxetine) and the other one experienced substantial improvement (pregabalin), over a period now lasting for more than a year.. Pregabalin and duloxetine, in particular, should be further investigated as possible medication for the treatment of PGAD.

Topics: Adult; Anticonvulsants; Duloxetine Hydrochloride; Female; gamma-Aminobutyric Acid; Humans; Pregabalin; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Thiophenes; Treatment Outcome

Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Dose-Response Relationship, Drug; Drug Therapy, Combination; gamma-Aminobutyric Acid; Humans; Male; Pregabalin; Sexual Dysfunction, Physiological